530317 — Godavari Drugs Income Statement
0.000.00%
- IN₹731.29m
- IN₹1.32bn
- IN₹1.13bn
- 62
- 62
- 30
- 52
Annual income statement for Godavari Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,227 | 1,611 | 1,596 | 1,567 | 1,134 |
Cost of Revenue | |||||
Gross Profit | 261 | 307 | 316 | 359 | 317 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,141 | 1,515 | 1,514 | 1,455 | 1,040 |
Operating Profit | 86 | 95.9 | 82.1 | 112 | 93.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 57.1 | 70.2 | 49.3 | 69.2 | 56.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 41.3 | 52.5 | 37.9 | 55.5 | 43.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 41.3 | 52.5 | 37.9 | 55.5 | 43.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 41.3 | 52.5 | 37.9 | 55.5 | 43.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.48 | 6.97 | 4.8 | 7.47 | 5.82 |